Your browser doesn't support javascript.
Immunoreactive peptide maps of SARS-CoV-2.
Mishra, Nischay; Huang, Xi; Joshi, Shreyas; Guo, Cheng; Ng, James; Thakkar, Riddhi; Wu, Yongjian; Dong, Xin; Li, Qianlin; Pinapati, Richard S; Sullivan, Eric; Caciula, Adrian; Tokarz, Rafal; Briese, Thomas; Lu, Jiahai; Lipkin, W Ian.
  • Mishra N; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA. nm2641@cumc.columbia.edu.
  • Huang X; Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Joshi S; Center for Infection and Immunity, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Guo C; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Ng J; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Thakkar R; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Wu Y; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Dong X; Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Li Q; Center for Infection and Immunity, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Pinapati RS; Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Sullivan E; Center for Infection and Immunity, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Caciula A; Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Tokarz R; School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Briese T; Nimble Therapeutics Inc, Madison, WI, USA.
  • Lu J; Nimble Therapeutics Inc, Madison, WI, USA.
  • Lipkin WI; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.
Commun Biol ; 4(1): 225, 2021 02 12.
Article in English | MEDLINE | ID: covidwho-1387490
ABSTRACT
Serodiagnosis of SARS-CoV-2 infection is impeded by immunological cross-reactivity among the human coronaviruses (HCoVs) SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, 229E, HKU1, and NL63. Here we report the identification of humoral immune responses to SARS-CoV-2 peptides that may enable discrimination between exposure to SARS-CoV-2 and other HCoVs. We used a high-density peptide microarray and plasma samples collected at two time points from 50 subjects with SARS-CoV-2 infection confirmed by qPCR, samples collected in 2004-2005 from 11 subjects with IgG antibodies to SARS-CoV-1, 11 subjects with IgG antibodies to other seasonal human coronaviruses (HCoV), and 10 healthy human subjects. Through statistical modeling with linear regression and multidimensional scaling we identified specific peptides that were reassembled to identify 29 linear SARS-CoV-2 epitopes that were immunoreactive with plasma from individuals who had asymptomatic, mild or severe SARS-CoV-2 infections. Larger studies will be required to determine whether these peptides may be useful in serodiagnostics.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides / Peptide Mapping / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Limits: Animals / Humans Language: English Journal: Commun Biol Year: 2021 Document Type: Article Affiliation country: S42003-021-01743-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides / Peptide Mapping / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Limits: Animals / Humans Language: English Journal: Commun Biol Year: 2021 Document Type: Article Affiliation country: S42003-021-01743-9